![C:\\Users\\bxb235\\Desktop\\PS_HOR_RGB_2C_forToolkit.png](media/image1.png){width="1.5833333333333333in"
height="0.6666666666666666in"}

# HRP-591 - Protocol for Human Subject Research**

## Protocol Title:

Knowledge about and attitudes toward open science practices among Penn State researchers

## Principal Investigator:

Name: Rick O. Gilmore

Department: Psychology

Telephone: 814-865-3664

E-mail Address: rog1\@psu.edu

## Version Date:**

20221102

## Clinicaltrials.gov Registration #:

Not applicable

**[Important Instructions for Using This Protocol Template:]{.underline}**

This template is provided to help investigators prepare a protocol that
includes the necessary information needed by the IRB to determine
whether a study meets all applicable criteria for approval.

1.  **GENERAL INSTRUCTIONS**[^1]**:**

    -   Prior to completing this protocol, ensure that you are using the
        > most recent version by verifying the protocol template version
        > date in the footer of this document with the current version
        > provided in the CATS IRB Library.

    -   Do not change the protocol template version date located in the
        > footer of this document.

    -   Some of the items may not be applicable to all types of
        > research. If an item is not applicable, please indicate as
        > such or skip question(s) if indicated in any of the
        > instructional text.

    -   **GRAY INSTRUCTIONAL BOXES:** Type your protocol responses
        > [below]{.underline} the gray instructional boxes of guidance
        > language. If the section or item is not applicable, indicate
        > not applicable.

-   **Do NOT delete the instructional boxes from the final version of
    the protocol.**

```{=html}
<!-- -->
```
-   The protocol should be written in lay language. Do **NOT** copy and
    > paste grant proposal information into the protocol.

-   Add the completed protocol template to your study in CATS IRB
    > (<http://irb.psu.edu>) on the "Basic Information" page.

    1.  **CATS IRB LIBRARY:**

```{=html}
<!-- -->
```
-   Documents referenced in this protocol template (e.g., SOP's,
    Worksheets, Checklists, and Templates) can be accessed by clicking
    the Library link in CATS IRB (<http://irb.psu.edu>).

    1.  **PROTOCOL REVISIONS:**

```{=html}
<!-- -->
```
-   When making revisions to this protocol as requested by the IRB,
    please follow the instructions outlined in the guides available in
    the Help Center in CATS IRB (<http://irb.psu.edu>) for using track
    changes.

-   Update the Version Date on page 1 each time this document is
    submitted to the IRB office with revisions.

**If you need help...**

**All locations:**

**Human Research Protection Program**

Office for Research Protections

101 Technology Center\
University Park, PA 16802-7014\
Phone: 814-865-1775\
Fax: 814-863-8699\
Email: [irb-orp@psu.edu](mailto:ORProtections@psu.edu)

[**https://www.research.psu.edu/irb**](https://www.research.psu.edu/irb)

# Table of Contents

## [1.0 Objectives](#objectives)

## [2.0 Background](#background)

## [3.0 Inclusion and Exclusion Criteria](#inclusion-and-exclusion-criteria)

## [4.0 Recruitment Methods](#recruitment-methods)

## [5.0 Consent Process and Documentation](#consent-process-and-documentation)

## [6.0 HIPAA Research Authorization and/or Waiver or Alteration of Authorization](#hipaa-research-authorization-andor-waiver-or-alteration-of-authorization)

## [7.0 Study Design and Procedures](#study-design-and-procedures)

## [8.0 Number of Subjects and Statistical Plan](#number-of-subjects-and-statistical-plan)

## [9.0 Data and Safety Monitoring Plan](#data-and-safety-monitoring-plan)

## [10.0 Risks](#risks)

## [11.0 Potential Benefits to Subjects and Others](#_Toc117767339)

## [12.0 Sharing Results with Subjects](#sharing-results-with-subjects)

## [13.0 Subject Payment and/or Travel Reimbursements](#subject-payment-andor-travel-reimbursements)

## [14.0 Economic Burden to Subjects](#economic-burden-to-subjects)

## [15.0 Resources Available](#resources-available)

## [16.0 Other Approvals](#other-approvals)

## [17.0 Multi-Site Study](#_Toc117767345)

## [18.0 Adverse Event Reporting](#adverse-event-reporting)

## [19.0 Study Monitoring, Auditing, and Inspecting](#study-monitoring-auditing-and-inspecting)

## [20.0 Future Undetermined Research: Data and Specimen Banking](#future-undetermined-research-data-and-specimen-banking)

## [21.0 References](#references)

## [22.0 Confidentiality, Privacy and Data Management](#confidentiality-privacy-and-data-management)

**\
**

1.1 Objectives
  - 1.1  Study Objectives

> Describe the purpose, specific aims, or objectives. State the
> hypotheses to be tested.
>
> \[Type protocol text here\]

  - 1.2 Primary Study Endpoints

> State the primary endpoints to be measured in the study.
>
> Research typically has a primary objective or endpoint. Additional
> objectives and endpoints are secondary. The endpoints (or outcomes),
> determined for each study subject, are the quantitative measurements
> required by the objectives. Measuring the selected endpoints is the
> goal of a trial (examples: response rate and survival).

\[Type protocol text here or indicate as not applicable\]

  - 1.3 Secondary Study Endpoints

> State the secondary endpoints to be measured in the study.
>
> \[Type protocol text here or indicate as not applicable\]

2.0 Background 

## Scientific Background and Gaps

> Describe the scientific background and gaps in current knowledge.
>
> For clinical research studies being conducted at Penn State
> Health/Penn State College of Medicine, and for other non-PSH locations
> as applicable, describe the treatment/procedure that is considered
> standard of care (i.e., indicate how patients would be treated in
> non-investigational setting); and if applicable, indicate if the study
> procedure is available to patient without taking part in the study.

> \[Type protocol text here\]

## Previous Data

> Describe any relevant preliminary data.
>
> \[Type protocol text here\]

## Study Rationale

> Provide the scientific rationale for the research.
>
> \[Type protocol text here\]

# Inclusion and Exclusion Criteria

Create a numbered list below in sections 3.1 and 3.2 of criteria
subjects must meet to be eligible for study enrollment (e.g., age,
gender, diagnosis, etc.).

**Vulnerable Populations:**

You MAY NOT include members of these populations as subjects in your
research unless you indicate this in your inclusion criteria because
specific regulations apply to studies that involve vulnerable
populations.

> The checklists referenced below outline the determinations to be made
> by the IRB when reviewing research involving these populations. Review
> the checklists as these will help to inform your responses throughout
> the remainder of the protocol.

-   **Children --**Review "HRP-416- Checklist - Children"

-   **Pregnant Women** -- Review "HRP-412- Checklist - Pregnant Women"

-   **Cognitively Impaired Adults-** Review "HRP-417- Checklist -
    > Cognitively Impaired Adults"

-   **Prisoners-** Review "HRP-415- Checklist - Prisoners"

-   **Neonates of uncertain viability or non-viable neonates-** Review
    > "HRP-413- Checklist - Non-Viable Neonates" or "HRP-414-
    > Checklist - Neonates of Uncertain Viability"

> \[Do not type here\]

## Inclusion Criteria

### Create a numbered list of the inclusion criteria that define who will be included in your final study sample (e.g., age, gender, condition, etc.)

> \[Type protocol text here\]
>
> **3.1.1 Does this research involve collecting data from individuals
> residing outside of the US?**
>

No

Yes -- identify the countries where data collection will take place

> \[Type protocol text here\]

## 

## Exclusion Criteria

### Create a numbered list of the exclusion criteria that define who will be excluded in your study.

## \[Type protocol text here\]

## Early Withdrawal of Subjects

### 

### Criteria for removal from study

### Insert subject withdrawal criteria (e.g., safety reasons, failure of subject to adhere to protocol requirements, subject consent withdrawal, disease progression, etc.).

> \[Type protocol text here or indicate as not applicable\]

### Follow-up for withdrawn subjects

### Describe when and how to withdraw subjects from the study; the type and timing of the data to be collected for withdrawal of subjects; whether and how subjects are to be replaced; the follow-up for subjects withdrawn from investigational treatment.

> \[Type protocol text here or indicate as not applicable\]

4.  # Recruitment Methods

    -   Upload recruitment materials for your study in CATS IRB
        > (<http://irb.psu.edu>). **DO NOT** include the actual
        > recruitment wording in this protocol.

    -   StudyFinder: If StudyFinder (<http://studyfinder.psu.edu>) is to
        > be used for recruitment purposes, separate recruitment
        > documents do not need to be uploaded in CATS IRB. The
        > necessary information will be captured from the StudyFinder
        > page in your CATS IRB study.

    -   Any eligibility screening questions (verbal/phone scripts,
        > email, etc.) used when contacting potential participants must
        > be uploaded to your study in CATS IRB (<http://irb.psu.edu>).

> \[Do not type here\]

## Identification of subjects

> Describe the source of subjects and the methods that will be used to
> identify potential subjects (e.g., organizational listservs,
> established recruitment databases, subject pools, medical or school
> records, interactions during a clinic visit, etc.). If not recruiting
> subjects directly (e.g., database query for eligible records or
> samples) state what will be queried, how and by whom.
>
> StudyFinder:

-   If you intend to use StudyFinder (<http://studyfinder.psu.edu>) for
    recruitment purposes, include this method in this section.

-   Information provided in this protocol, including the description of
    study procedures, compensation, and recruitment, needs to be
    consistent with information provided on the StudyFinder page in your
    CATS IRB study.

> For Penn State Health submissions using Enterprise Information
> Management (EIM) for recruitment, and for non-Hershey locations as
> applicable, attach your EIM Design Specification form in CATS IRB
> (<http://irb.psu.edu>). See "HRP-103- Investigator Manual, Study
> Recruitment" for additional information.
>
> **DO NOT** include the actual recruitment material or wording in this
> protocol.
>
> \[Type protocol text here\]

## 

## Recruitment process

> Describe how potential subjects first learn about this research
> opportunity or indicate 'not applicable' if subjects will not be
> prospectively recruited to participate in the research. Subject
> recruitment can involve various methods (e.g., approaching potential
> subjects in person, contacting potential subjects via email, letters,
> telephone, ResearchMatch, or advertising to a general public via
> flyers, websites, StudyFinder, newspaper, television, and radio etc.).
> **DO NOT** include the actual recruitment material or wording in this
> protocol.
>
> \[Do not type here\]

### How potential subjects will be recruited.

> \[Type protocol text here or indicate as not applicable\]

### Where potential subjects will be recruited.

> \[Type protocol text here or indicate as not applicable\]

### When potential subjects will be recruited.

> \[Type protocol text here or indicate as not applicable\]

4.  **Describe the eligibility screening process. Screening begins when
    the investigator obtains information about or from a prospective
    participant in order to determine their eligibility.**

> Eligibility screening is occurring *before* consent\*
>
> Eligibility screening is occurring *after* consent
>
> Consent is not being obtained in this research
>
> Not applicable - Eligibility screening is not being done in this
> research
>
> \[Type protocol text here\]
>
> \*Unless informed consent is waived by the IRB, screening before
> consent is only permitted when screening activities are limited to the
> collection of information through oral or written communication OR
> when identifiable private information or identifiable biospecimens is
> obtained by accessing records or stored identifiable biospecimens.
> Screening before consent is not permitted if data will be used for
> activities other than eligibility screening/recruitment (e.g., data
> analysis). In some studies, these procedures may not take place unless
> HIPAA Authorization is obtained OR a waiver of HIPAA Authorization
> when applicable for the screening procedures is approved by the IRB.

# Consent Process and Documentation 

> Refer to the following materials:

-   The "HRP-090- SOP - Informed Consent Process for Research" outlines
    > the process for obtaining informed consent.

-   The "HRP-091-- SOP - Written Documentation of Consent" describes how
    > the consent process will be documented.

-   The "HRP-314- Worksheet - Criteria for Approval" section 7 lists the
    > required elements of consent.

-   The "HRP-312- Worksheet - Exemption Determination" includes
    > information on requirements for the consent process for exempt
    > research. In addition, the CATS IRB Library contains consent
    > guidance and templates for exempt research.

-   The CATS IRB library contains various consent templates for
    > expedited or full review research that are designed to include the
    > required information.

-   Add the consent document(s) to your study in CATS IRB
    > (<http://irb.psu.edu>). Links to Penn State's consent templates
    > are available in the same location where they are uploaded. **DO
    > NOT** include the actual consent wording in this protocol.

\[Do not type here\]

## Consent Process:

> **Check all applicable boxes below:**
>
> **Informed consent will be sought and documented with a written
> consent form** *\[Complete Sections 5.2 and 5.6; If this is the only
> box checked, mark Sections 5.3, 5.4 and 5.5 as 'Not applicable'\]*
>
> **Implied or verbal consent will be obtained -- subjects will not sign
> a consent form (waiver of written documentation of consent)**
> *\[Complete Sections 5.2, 5.3 and 5.6; If this is the only box
> checked, mark Sections 5.4 and 5.5 as 'Not applicable'\]*
>
> **Informed consent will be sought but some of the elements of informed
> consent will be omitted or altered (e.g., deception).** *\[Complete
> section 5.2, 5.4 and 5.6; If this is the only box checked, mark
> Section 5.5 as 'Not applicable'\]*
>
> **Informed consent will not be obtained -- request to completely waive
> the informed consent requirement.** *\[Complete Section 5.5; If this
> is the only box checked, mark Sections 5.2, 5.3, 5.4 and 5.6 as 'Not
> applicable'\]*
>
> **[Exempt Research]{.underline}: If you believe that the research
> activities outlined meet one or more of the criteria outlined in
> "HRP-312- Worksheet- Exemption Determination", check this box. By
> checking this box, you are verifying that the exempt consent process
> will disclose the following:**
>
> Penn State affiliation; name and contact information for the
> researcher and advisor (if the researcher is a student); the
> activities involve research; the procedures to be performed;
> participation is voluntary; that there are adequate provisions to
> maintain the privacy interests of subjects and the confidentiality of
> the data.
>
> **If the research includes the use of student educational records
> include the following language in this section:** The parent or
> eligible student will provide a signed and dated written consent that
> discloses: the records that may be disclosed; the purpose of the
> disclosure; the party or class of parties to whom the disclosure may
> be made; if a parent or adult student requests, the school will
> provide him or her with a copy of the records disclosed; if the parent
> of a student who is not an adult so requests, the school will provide
> the student with a copy of the records disclosed.
>
> **Note: If this box has been checked, mark Sections 5.3, 5.4, 5.5, and
> 5.6 as "Not applicable." If the investigator's assessment is
> inaccurate, an IRB Analyst will request revision to the protocol and
> ask that consent forms and recruitment materials be submitted. Except
> for exemptions where Limited IRB Review is required (see "HRP-312-
> Worksheet- Exemption Determination") or where otherwise requested by
> the IRB, consent forms and recruitment materials are generally not
> reviewed nor approved by the PSU HRPP for research undergoing exempt
> review.**

## Obtaining Informed Consent 

### 

### Consent Process 

> Describe the consent process, including when and where it will take
> place.
>
> \[Type protocol text here\]

### Coercion or Undue Influence during Consent 

> Describe the steps that will be taken to minimize the possibility of
> coercion or undue influence in the consent process.
>
> \[Type protocol text here\]

## Waiver of Written Documentation of Consent 

> Review "HRP -- 411 -- Checklist -- Waiver of Written Documentation of
> Consent."

### Indicate which of the following conditions applies to this research:

> The research presents no more that minimal risk of harm to subjects
> and involves no procedures for which written consent is normally
> required outside of the research context.
>
> OR
>
> The only record linking the subject and the research would be the
> consent document and the principal risk would be potential harm
> resulting from a breach of confidentiality. Each subject will be asked
> whether the subject wants documentation linking the subject with the
> research, and the subject's wishes will govern. (*Note: This condition
> is not applicable for FDA-regulated research. If this category is
> chosen, include copies of a consent form and /or parental permission
> form for participants who want written documentation linking them to
> the research.)*
>
> OR
>
> If the subjects or legally authorized representatives are members of a
> distinct cultural group or community in which signing forms is not the
> norm, that the research presents no more than minimal risk of harm to
> subjects and provided there is an appropriate alternative mechanism
> for documenting that informed consent was obtained. (*Note: This
> condition is not applicable for FDA-regulated research.)*
>
> For distinct cultural groups, describe the alternative mechanism for
> documenting that informed consent was obtained:
>
> \[Type protocol text here\]

### Indicate what materials, if any, will be used to inform potential subjects about the research (e.g., a letter accompanying a questionnaire, verbal script, or implied consent form)

> \[Type protocol text here or indicate as not applicable\]

## Informed consent will be sought but some of the elements of informed consent will be omitted or altered (e.g., deception).

> Review "HRP-410-Checklist -Waiver or Alteration of Consent Process" to
> ensure that you have provided sufficient information.

### Indicate the elements of informed consent to be omitted or altered

> \[Type protocol text here or indicate as not applicable\]

### Indicate why the research could not practicably be carried out without the omission or alteration of consent elements

> \[Type protocol text here or indicate as not applicable\]

### Describe why the research involves no more than minimal risk to subjects.

> \[Type protocol text here or indicate as not applicable\]

### Describe why the alteration/omission will not adversely affect the rights and welfare of subjects.

> \[Type protocol text here or indicate as not applicable\]

### If the research involves using identifiable private information or identifiable biospecimens, describe why the research could not practicably be carried out without using such information or biospecimens in an identifiable format.

> \[Type protocol text here or indicate as not applicable\]

### Debriefing 

> Explain whether and how subjects will be debriefed after participation
> in the study. If subjects will not be debriefed, provide a
> justification for not doing so. Add any debriefing materials to the
> study in CATS IRB.
>
> \[Type protocol text here or indicate as not applicable\]

## Informed consent will not be obtained -- request to completely waive the informed consent requirement

> Review "HRP-410-Checklist -Waiver or Alteration of Consent Process" to
> ensure that you have provided sufficient information.

### Indicate why the research could not practicably be carried out without the waiver of consent

> \[Type protocol text here or indicate as not applicable\]

### Describe why the research involves no more than minimal risk to subjects.

> \[Type protocol text here or indicate as not applicable\]

### Describe why the alteration/omission will not adversely affect the rights and welfare of subjects.

> \[Type protocol text here or indicate as not applicable\]

### If the research involves using identifiable private information or identifiable biospecimens, describe why the research could not practicably be carried out without using such information or biospecimens in an identifiable format.

> \[Type protocol text here or indicate as not applicable\]

### Additional pertinent information after participation

> Explain if subjects will be provided with additional pertinent
> information after participation.
>
> \[Type protocol text here or indicate as not applicable\]

6.  ## Consent -- Other Considerations 

    1.  ### Non-English-Speaking Subjects

> Indicate what language(s) other than English are understood by
> prospective subjects or representatives.
>
> If subjects who do not speak English will be enrolled, describe the
> process to ensure that the oral and written information provided to
> those subjects will be in that language. Indicate the language that
> will be used by those obtaining consent.
>
> Indicate whether the consent process will be documented in writing
> with the long form of the consent documentation or with the short form
> of the consent documentation. Review "HRP-091 --SOP- Written
> Documentation of Consent" and "HRP-103 -Investigator Manual" to ensure
> that you have provided sufficient information.
>
> \[Type protocol text here or indicate as not applicable\]

### Cognitively Impaired Adults

> Refer "HRP-417 -CHECKLIST- Cognitively Impaired Adults" for
> information about research involving cognitively impaired adults as
> subjects.

#### Capability of Providing Consent

> Describe the process to determine whether an individual is capable of
> consent.
>
> \[Type protocol text here or indicate as not applicable\]

#### Adults Unable to Consent

> Describe whether and how informed consent will be obtained from the
> legally authorized representative. Describe who will be allowed to
> provide informed consent. Describe the process used to determine these
> individual's authority to consent to research.
>
> For research conducted in the state of Pennsylvania, review "HRP-013
> -SOP- Legally Authorized Representatives, Children and Guardians" to
> be aware of which individuals in the state of Pennsylvania meet the
> definition of "legally authorized representative."
>
> For research conducted outside of the state of Pennsylvania, provide
> information that describes which individuals are authorized under
> applicable law to consent on behalf of a prospective subject to their
> participation in the procedure(s) involved in this research. One
> method of obtaining this information is to have a legal counsel or
> authority review your protocol along with the definition of "children"
> in "HRP-013 -SOP- Legally Authorized Representatives, Children, and
> Guardians."
>
> \[Type protocol text here or indicate as not applicable\]

##### Assent of Adults Unable to Consent

> Describe the process for assent of the subjects. Indicate whether
> assent will be required of all, some, or none of the subjects. If
> some, indicate which subjects will be required to assent and which
> will not.
>
> If assent will not be obtained from some or all subjects, provide an
> explanation of why not.
>
> Describe whether assent of the subjects will be documented and the
> process to document assent. The IRB allows the person obtaining assent
> to document assent on the consent document and does not routinely
> require assent documents and does not routinely require subjects to
> sign assent documents.
>
> \[Type protocol text here or indicate as not applicable\]

### Subjects who are not yet adults (infants, children, teenagers) 

#### 

2.  1.  #### Parental Permission

> Describe whether and how parental permission will be obtained. If
> permission will be obtained from individuals other than parents,
> describe who will be allowed to provide permission. Describe the
> process used to determine these individual's authority to consent to
> each child's general medical care.
>
> For research conducted in the state of Pennsylvania, review
> "HRP-013-SOP- Legally Authorized Representatives, Children and
> Guardians" to be aware of which individuals in the state of
> Pennsylvania meet the definition of "children."
>
> For research conducted outside of the state of Pennsylvania, provide
> information that describes which persons have not attained the legal
> age for consent to treatments or procedures involved in the research,
> under the applicable law of the jurisdiction in which research will be
> conducted. One method of obtaining this information is to have a legal
> counsel or authority review your protocol along with the definition of
> "children" in "HRP-013-SOP- Legally Authorized Representatives,
> Children, and Guardians."
>
> \[Type protocol text here or indicate as not applicable\]

#### Assent of subjects who are not yet adults

> Indicate whether assent will be obtained from all, some, or none of
> the children. If assent will be obtained from some children, indicate
> which children will be required to assent. When assent of children is
> obtained describe whether and how it will be documented.
>
> \[Type protocol text here or indicate as not applicable\]

# HIPAA Research Authorization and/or Waiver or Alteration of Authorization

> This section is about the access, use or disclosure of Protected
> Health Information (PHI). PHI is individually identifiable health
> information (i.e., health information containing one or more 18
> identifiers) that is transmitted or maintained in any form or medium
> by a Covered Entity or its Business Associate. A Covered Entity is a
> health plan, a health care clearinghouse or health care provider who
> transmits health information in electronic form. See "HRP-103
> -Investigator Manual" for a list of the 18 identifiers.
>
> If requesting a waiver/alteration of HIPAA authorization, complete
> sections 6.2 and 6.3 in addition to section 6.1. The Privacy Rule
> permits waivers (or alterations) of authorization if the research
> meets certain conditions. Include only information that will be
> accessed with the waiver/alteration.
>
> \[Do not type here\]

## Authorization and/or Waiver or Alteration of Authorization for the Uses and Disclosures of PHI

> **Check all that apply:**
>
> **Not applicable, no identifiable protected health information (PHI)
> is accessed, used, or disclosed in this study.** *\[Mark all parts of
> sections 6.2 and 6.3 as not applicable\]*
>
> **Authorization will be obtained and documented as part of the consent
> process.** *\[If this is the only box checked, mark sections 6.2 and
> 6.3 as not applicable\]*
>
> **Partial waiver is requested for recruitment purposes only (Check
> this box if patients' medical records will be accessed to determine
> eligibility before consent/authorization has been obtained).**
> *\[Complete all parts of sections 6.2 and 6.3\]*
>
> **Full waiver is requested for entire research study (e.g., medical
> record review studies).** *\[Complete all parts of sections 6.2 and
> 6.3\]*
>
> **Alteration is requested to waive requirement for written
> documentation of authorization (verbal or implied authorization will
> be obtained).** *\[Complete all parts of sections 6.2 and 6.3\]*

## Waiver or Alteration of Authorization for the Uses and Disclosures of PHI

### 

### Access, use or disclosure of PHI representing no more than a minimal risk to the privacy of the individual

#### 

#### Plan to protect PHI from improper use or disclosure

> Include the following statement as written -- DO NOT ALTER OR DELETE
> unless this section is not applicable because the research does not
> involve a waiver of authorization. **If the section is
> [not]{.underline} applicable, [remove]{.underline} the statement and
> [indicate as not applicable]{.underline}.**
>
> *Information is included in the "Confidentiality, Privacy and Data
> Management" section of this protocol or in "HRP-598 -- Research Data
> Plan Review Form".*

#### Plan to destroy identifiers or a justification for retaining identifiers 

> Describe the plan to destroy the identifiers at the earliest
> opportunity consistent with the conduct of the research. Include when
> and how identifiers will be destroyed. If identifiers will be
> retained, provide the legal, health or research justification for
> retaining the identifiers.

### 

> \[Type protocol text here or indicate as not applicable\]

### Explanation for why the research could not practicably be conducted without access to and use of PHI

> Provide reasons why this research could not practicably be carried out
> without access to and use of PHI.

### 

> \[Type protocol text here or indicate as not applicable\]

### Explanation for why the research could not practicably be conducted without the waiver or alteration of authorization

> Provide reasons why this research could not practicably be carried out
> without the waiver or alternation of authorization.
>
> \[Type protocol text here or indicate as not applicable\]

## Waiver or alteration of authorization statements of agreement

> By submitting this study for review with a waiver of authorization,
> you agree to the following statement -- DO NOT ALTER OR DELETE unless
> this section is not applicable because the research does not involve a
> waiver or alteration of authorization. **If the section is
> [not]{.underline} applicable, [remove]{.underline} the statement and
> [indicate as not applicable.]{.underline}**
>
> *Protected health information obtained as part of this research will
> not be reused or disclosed to any other person or entity, except as
> required by law, for authorized oversight of the research study, or
> for other permitted uses and disclosures according to federal
> regulations.*
>
> *The research team will collect only information essential to the
> study and in accord with the 'Minimum Necessary' standard (information
> reasonably necessary to accomplish the objectives of the research) per
> federal regulations.*
>
> *Access to the information will be limited, to the greatest extent
> possible, within the research team. All disclosures or releases of
> identifiable information granted under this waiver will be accounted
> for and documented.*

# Study Design and Procedures

Data collection materials that will be seen or used by subjects in your
study must be uploaded to CATS IRB (<http://irb.psu.edu>). **DO NOT**
include any actual data collection materials in this protocol (e.g.,
actual survey or interview questions).

\[Do not type here\]

## Study Design

> Describe and explain the study design.
>
> \[Type protocol text here\]

## Study Procedures

> Provide a step-by-step description of all research procedures being
> conducted (broken down by visit, if applicable) including such
> information as below (where and when applicable); describe the
> following:

-   HOW: (e.g., data collection via interviews, focus groups, forms such
    > as surveys and questionnaires, medical/school records,
    > audio/video/digital recordings, photographs, EKG procedures, MRI,
    > mobile devices such as electronic tablets/cell phones,
    > observations, collection of specimens, experimental drug/device
    > testing, manipulation of behavior/use of deception, computer
    > games, etc.) For surveys, indicate if subjects are able to skip
    > questions that they don't want to answer.

-   WHERE: (e.g., classrooms, labs, internet/online, places of business,
    > medical settings, public spaces, etc.)

> \[Type protocol text here\]

### Visit 1 or Day 1 or Pre-test, etc. 

> Provide a description of what procedures will be performed on visit 1
> or day 1 or pre-test in order of how these will be done. If your study
> only involves one session or visit, use this section only and delete
> 7.2.2.
>
> \[Type protocol text here\]

### Visit 2 or Day 2 or Post-test, etc. (If applicable) 

> Provide a description of what procedures will be performed on visit 2
> or day 2 or post-test in order of how these will be done. If your
> study involves more than two sessions or visits replicate this section
> for each additional session or visit (e.g., 7.2.3, 7.2.4, etc.). If
> your study involves only one session or visit, delete this section.
>
> \[Type protocol text here or delete this section\]

## Duration of Participation

> Describe how long subjects will be involved in this research study.
> Include the number of sessions and the duration of each session -
> consider the total number of minutes, hours, days, months, years, etc.
>
> \[Type protocol text here\]

8.  # Number of Subjects and Statistical Plan

    1.  ## Number of Subjects

## Indicate the maximum number of subjects to be accrued/enrolled, to include all persons who sign consent for the study. If applicable, distinguish between the number of subjects who are expected to be enrolled and screened, and the number of subjects needed to complete the research procedures (i.e., numbers of subjects excluding screen failures.)

> \[Type protocol text here\]

## Sample Size Determination

> If applicable, provide a justification of the sample size outlined in
> section 8.1 to include reflections on, or calculations of, the power
> of the study.
>
> \[Type protocol text here or indicate as not applicable\]

## Statistical or Analytic Methods

> Describe the statistical methods (or non-statistical methods of
> analysis) that will be employed.
>
> \[Type protocol text here\]

# Data and Safety Monitoring Plan

> **This section is required when research involves more than Minimal
> Risk to subjects as defined in "HRP-001 SOP- Definitions."**
>
> Minimal Risk is defined as the probability and magnitude of harm or
> discomfort anticipated in the research that are not greater in and of
> themselves than those ordinarily encountered in daily life or during
> the performance of routine physical or psychological examinations or
> tests. For research involving prisoners, Minimal Risk is the
> probability and magnitude of physical or psychological harm that is
> normally encountered in the daily lives, or in the routine medical,
> dental, or psychological examination of healthy persons.
>
> **Please complete each section below if the research involves more
> than minimal risk to subjects or indicate not applicable.**
>
> \[Do not type here\]

## Periodic evaluation of data

> Describe the plan to periodically evaluate the data collected
> regarding both harms and benefits to determine whether subjects remain
> safe.
>
> \[Type protocol text here or indicate as not applicable\]

2.  **Data that are reviewed**

## Describe the data that are reviewed, including safety data, untoward events, and efficacy data.

> \[Type protocol text here or indicate as not applicable\]

## Method of collection of safety information

> Describe the method by which the safety information will be collected
> (e.g., with case report forms, at study visits, by telephone calls and
> with subjects).
>
> \[Type protocol text here or indicate as not applicable\]

## Frequency of data collection

> Describe the frequency of data collection, including when safety data
> collection starts.
>
> \[Type protocol text here or indicate as not applicable\]

## Individuals reviewing the data

> Identify the individuals who will review the data. The plan might
> include establishing a data and safety monitoring committee and a plan
> for reporting data monitoring committee findings to the IRB and the
> sponsor.
>
> \[Type protocol text here or indicate as not applicable\]

## Frequency of review of cumulative data

> Describe the frequency or periodicity of review of cumulative data.
>
> \[Type protocol text here or indicate as not applicable\]

## Statistical tests

> Describe the statistical tests for analyzing the safety data to
> determine whether harms are occurring.
>
> \[Type protocol text here or indicate as not applicable\]

## Suspension of research

> Describe any conditions that trigger an immediate suspension of
> research.
>
> \[Type protocol text here or indicate as not applicable\]

# Risks

> List the reasonably foreseeable risks, discomforts, hazards, or
> inconveniences to the subjects related the subjects' participation in
> the research. Include as may be useful for the IRB's consideration, a
> description of the probability, magnitude, duration, and reversibility
> of the risks. Consider all types of risk including physical,
> psychological, social, legal, and economic risks. **Note: Loss of
> confidentiality is a potential risk when conducting human subject
> research and must be listed here.**

-   If applicable, indicate which procedures may have risks to the
    > subjects that are currently unforeseeable.

-   If applicable, indicate which procedures may have risks to an embryo
    > or fetus should the subject be or become pregnant.

-   If applicable, describe risks to others who are not subjects.

\[Type protocol text here\]

# Potential Benefits to Subjects and Others 

## 

## Potential Benefits to Subjects

> Describe the potential benefits that individual subjects may
> experience from taking part in the research. If there is no direct
> benefit to subjects, indicate as such. Compensation is not considered
> a benefit. Compensation should be addressed in section 13.0.
>
> \[Type protocol text here or indicate "none" if there is no direct
> benefit to subjects\]

## Potential Benefits to Others

> Describe the potential benefits to society or others.
>
> \[Type protocol text here\]

# Sharing Results with Subjects

## Describe whether results (study results or individual subject results, such as results of investigational diagnostic tests, genetic tests, or incidental findings) will be shared with subjects or others (e.g., the subject's primary care physicians) and if so, describe how information will be shared. 

# 

> \[Type protocol text here or indicate as not applicable\]

# Subject Payment and/or Travel Reimbursements

> Describe the amount, type (cash, check, gift card, other) and timing
> of any subject payment or travel reimbursement. If there is **no**
> subject payment or travel reimbursement, indicate as not applicable.
>
> Extra or Course Credit: Describe the amount of credit **and** the
> available alternatives. Alternatives should be equal in time and
> effort to the amount of course or extra credit offered. It is not
> acceptable to indicate that the amount of credit is to be determined
> or at the discretion of the instructor of the course.
>
> Approved Subject Pool: Indicate which approved subject pool will be
> used; include in response below that course credit will be given and
> alternatives will be offered as per the approved subject pool
> procedures.
>
> \[Type protocol text here or indicate as not applicable\]

# Economic Burden to Subjects

## Costs

> Describe any costs that subjects may be responsible for because of
> participation in the research.

> \[Type protocol text here or indicate as not applicable\]

## Compensation for research-related injury

> **If the research involves more than Minimal Risk to subjects,
> describe the available compensation in the event of research related
> injury.**
>
> **If there is no sponsor agreement that addresses compensation for
> medical care for research subjects with a research-related injury,
> include the following text as written - DO NOT ALTER OR DELETE:**
>
> It is the policy of the institution to provide neither financial
> compensation nor free medical treatment for research-related injury.
> In the event of injury resulting from this research, medical treatment
> is available but will be provided at the usual charge. Costs for the
> treatment of research-related injuries will be charged to subjects or
> their insurance carriers.
>
> **For sponsored research studies with a research agreement with the
> sponsor that addresses compensation for medical care for
> research-related injuries, include the following text as written -**
> **DO NOT ALTER OR DELETE:**
>
> It is the policy of the institution to provide neither financial
> compensation nor free medical treatment for research-related injury.
> In the event of injury resulting from this research, medical treatment
> is available but will be provided at the usual charge. Such charges
> may be paid by the study sponsor as outlined in the research agreement
> and explained in the consent form.
>
> \[Enter protocol text as outlined in the instructions here or indicate
> as not applicable\]

# Resources Available

## Facilities and locations

> Identify and describe the facilities, sites, and locations where
> recruitment and study procedures will be performed.
>
> If research will be conducted outside the United States, describe
> site-specific regulations or customs affecting the research, and
> describe the process for obtaining local ethical review. Also,
> describe the principal investigator's experience conducting research
> at these locations and familiarity with local culture.

> \[Type protocol text here\]

## Feasibility of recruiting the required number of subjects

> Indicate the number of potential subjects to which the study team has
> access. Indicate the percentage of those potential subjects needed for
> recruitment.
>
> \[Type protocol text here\]

## PI Time devoted to conducting the research

> Describe how the PI will ensure that a sufficient amount of time will
> be devoted to conducting and completing the research. Consider outside
> responsibilities as well as other on-going research for which the PI
> is responsible. Please only provide a response for the principal
> investigator -- do **not** include information about any other study
> team members.
>
> \[Type protocol text here\]

## Availability of medical or psychological resources

> Describe the availability of medical or psychological resources that
> subjects might need as a result of their participation in the study.
>
> \[Type protocol text here or indicate as not applicable\]

## Process for informing Study Team

> Describe the training plans to ensure members of the research team are
> informed about the protocol and their duties.
>
> \[Type protocol text here or indicate as not applicable if the
> principal investigator is the only study team member listed on the
> CATS IRB submission\]

# Other Approvals

## Other Approvals from External Entities

> Describe any approvals that will be obtained prior to commencing the
> research (e.g., from engaged cooperating institutions IRBs who are
> also reviewing the research and other required review committees,
> community leaders, schools, research locations where research is to be
> conducted by the Penn State investigator, funding agencies, etc.).
>
> \[Type protocol text here or indicate as not applicable\]

## Internal PSU Ancillary Reviews

> DO NOT ALTER OR DELETE:
>
> Ancillary reviews are reviewed by other compliance groups or
> individuals within Penn State that inform the IRB's review of a new
> study or a modification to an existing study.
>
> PSU IRB may set applicable ancillary reviews for your study. Please
> refer to the "HRP-309 Worksheet -- Ancillary Review Matrix" for more
> information (found in the CATS Library).
>
> \[Do not type here\]

# Multi-Site Study

## If this is a multi-site study (i.e., a study in which two or more institutions coordinate, with each institution completing all research activities outlined in a specific protocol) and the Penn State PI is the lead investigator, describe the processes to ensure communication among sites in the sections below.

> \[Do not type here\]

## Other sites 

> List the name and location of all other participating sites. Provide
> the name, qualifications and contact information for the principal
> investigator at each site and indicate which IRB will be reviewing the
> study at each site.

\[Type protocol text here or indicate as not applicable\]

## Communication Plans

> Describe the plan for regular communication between the overall study
> director and the other sites to ensure that all sites have the most
> current version of the protocol, consent document, etc. Describe the
> process to ensure all modifications have been communicated to sites.
> Describe the process to ensure that all required approvals have been
> obtained at each site (including approval by the site's IRB of
> record). Describe the process for communication of problems with the
> research, interim results, and closure of the study.
>
> \[Type protocol text here or indicate as not applicable\]

## Data Submission and Security Plan

> Describe the process and schedule for data submission and provide the
> data security plan for data collected from other sites. Describe the
> process to ensure all engaged participating sites will safeguard data
> as required by local information security policies.
>
> \[Type protocol text here or indicate as not applicable\]

## Subject Enrollment

> Describe the procedures for coordination of subject enrollment and
> randomization for the overall project.
>
> \[Type protocol text here or indicate as not applicable\]

## Reporting of Adverse Events and New Information

> Describe how adverse events and other information will be reported
> from the clinical sites to the overall study director. Provide the
> timeframe for this reporting.
>
> \[Type protocol text here or indicate as not applicable\]

## Audit and Monitoring Plans

> Describe the process to ensure all local site investigators conduct
> the study appropriately. Describe any on-site auditing and monitoring
> plans for the study.
>
> \[Type protocol text here or indicate as not applicable\]

# Adverse Event Reporting

## Reporting Adverse Reactions and Unanticipated Problems to the Responsible IRB

> By submitting this study for review, you agree to the following
> statement -- DO NOT ALTER OR DELETE:
>
> *In accordance with applicable policies of The Pennsylvania State
> University Institutional Review Board (IRB), the investigator will
> report, to the IRB, any observed or reported harm (adverse event)
> experienced by a subject or other individual, which in the opinion of
> the investigator is determined to be (1) unexpected; and (2) probably
> related to the research procedures. Harms (adverse events) will be
> submitted to the IRB in accordance with the IRB policies and
> procedures.*

# Study Monitoring, Auditing, and Inspecting

## Auditing and Inspecting

> By submitting this study for review, you agree to the following
> statement -- DO NOT ALTER OR DELETE:
>
> *The investigator will permit study-related monitoring, audits, and
> inspections by the Penn State quality assurance program office(s),
> IRB, the sponsor, and government regulatory bodies, of all study
> related documents (e.g., source documents, regulatory documents, data
> collection instruments, study data etc.). The investigator will ensure
> the capability for inspections of applicable study-related facilities
> (e.g., pharmacy, diagnostic laboratory, etc.).*

# Future Undetermined Research: Data and Specimen Banking

> If this study is collecting **identifiable** data and/or specimens
> that will be banked for **future undetermined** **research**, please
> describe this process in the sections below. This information should
> not conflict with information provided in section 22 below OR the
> "HRP-598 -- Research Data Plan Review Form" regarding whether or not
> data and/or specimens will be associated with identifiers (directly or
> indirectly). If there are no plans to use identifiable data/specimens
> for future, undetermined research, then this section is **NOT
> applicable**.
>
> \[Do not type here\]

## Data and/or specimens being stored

## Identify what data and/or specimens will be stored, and the data associated with each specimen.

> \[Type protocol text here or indicate as not applicable\]

## Location of storage

> Identify the location where the data and/or specimens will be stored.
>
> \[Type protocol text here or indicate as not applicable\]

## Duration of storage

> Identify how long the data and/or specimens will be stored. If data
> and/or specimens will be stored indefinitely, indicate such.
>
> \[Type protocol text here or indicate as not applicable\]

## Access to data and/or specimens

> Identify who will have access to the data and/or specimens.

## \[Type protocol text here or indicate as not applicable\]

## Procedures to release data or specimens

> Describe the procedures to release the data and/or specimens,
> including: the process to request a release, approvals required for
> release, who can obtain data and/or specimens, and the data to be
> provided with the specimens.
>
> \[Type protocol text here or indicate as not applicable\]

## Process for returning results

> Describe the process for returning results about the use of the data
> and/or specimens.
>
> \[Type protocol text here or indicate as not applicable\]

# References

> List relevant references in the literature which highlight methods,
> controversies, and study outcomes.
>
> \[Type protocol text here or indicate as not applicable\]

# Confidentiality, Privacy and Data Management 

> **IMPORTANT: The following section is required for all locations
> EXCEPT Penn State Health and the College of Medicine. Penn State
> Health and College of Medicine should skip this section and complete
> "HRP-598 Research Data Plan Review Form." In order to avoid
> redundancy, for this section state "See the Research Data Plan Review
> Form" if you are conducting Penn State Health research. Delete all
> other sub-sections of section 22.**

**[For research being conducted at Penn State Health or by Penn State
Health researchers only]{.underline}: The research data security and
integrity plan is submitted using "HRP-598 -- Research Data Plan Review
Form."**

**In order to avoid redundancy, for this section state "See the Research
Data Plan Review Form" if you are conducting Penn State Health research.
[Delete all sub-sections of section 22.]{.underline}**

**[For all other research]{.underline}**: Complete the following
section. Please refer to [PSU Policy
AD95](https://policy.psu.edu/policies/ad95#C) for information regarding
information classification and security standards and requirements. It
is recommended that you work with local IT staff when planning to store,
process, or access data electronically to ensure that your plan can be
carried out locally and meets applicable requirements. If you have
questions about Penn State's Policy AD95 or standards or need a
consultation regarding data security, please contact Penn State IT --
Information Security at <security@psu.edu>.

## Which of the following identifiers will be recorded for the research project? Check all that apply. If none of the following identifiers will be recorded, do not check any of the boxes.

+--------------------------------------------------------+-----+-------+
|                                                        | H   | Elect |
|                                                        | ard | ronic |
|                                                        | C   |       |
|                                                        | opy | S     |
|                                                        | D   | tored |
|                                                        | ata |       |
|                                                        |     | Data  |
+========================================================+=====+=======+
| Names and/or initials (including on signed consent     |     |       |
| documents)                                             |     |       |
+--------------------------------------------------------+-----+-------+
| All geographic subdivisions smaller than a State,      |     |       |
| including street address, city, county, precinct, zip  |     |       |
| code, and their equivalent geocodes,                   |     |       |
+--------------------------------------------------------+-----+-------+
| All elements of dates (except year) for dates directly |     |       |
| related to an individual, including birth date,        |     |       |
| admission date, discharge date, date of death; and all |     |       |
| ages over 89 and all elements of dates (including      |     |       |
| year) indicative of such age, except that such ages    |     |       |
| and elements may be aggregated into a single category  |     |       |
| of age 90 or older                                     |     |       |
+--------------------------------------------------------+-----+-------+
| Telephone numbers                                      |     |       |
+--------------------------------------------------------+-----+-------+
| Fax numbers                                            |     |       |
+--------------------------------------------------------+-----+-------+
| Electronic mail addresses                              |     |       |
+--------------------------------------------------------+-----+-------+
| Social security numbers                                |     |       |
+--------------------------------------------------------+-----+-------+
| Medical record numbers                                 |     |       |
+--------------------------------------------------------+-----+-------+
| Health plan beneficiary numbers                        |     |       |
+--------------------------------------------------------+-----+-------+
| Account numbers                                        |     |       |
+--------------------------------------------------------+-----+-------+
| Certificate/license numbers                            |     |       |
+--------------------------------------------------------+-----+-------+
| Vehicle identifiers and serial numbers, including      |     |       |
| license plate numbers                                  |     |       |
+--------------------------------------------------------+-----+-------+
| Device identifiers and serial numbers                  |     |       |
+--------------------------------------------------------+-----+-------+
| Web Universal Resource Locators (URLs)                 |     |       |
+--------------------------------------------------------+-----+-------+
| Internet Protocol (IP) address numbers                 |     |       |
+--------------------------------------------------------+-----+-------+
| Biometric identifiers, including finger and voice      |     |       |
| prints                                                 |     |       |
+--------------------------------------------------------+-----+-------+
| Full face photographic images and any comparable       |     |       |
| images                                                 |     |       |
+--------------------------------------------------------+-----+-------+
| Any other unique identifying number, characteristic,   |     |       |
| or code (such as the pathology number)                 |     |       |
+--------------------------------------------------------+-----+-------+
| Study code number with linking list                    |     |       |
+--------------------------------------------------------+-----+-------+
| Genomic sequence data                                  |     |       |
+--------------------------------------------------------+-----+-------+
| State ID numbers                                       |     |       |
+--------------------------------------------------------+-----+-------+
| Passport numbers                                       |     |       |
+--------------------------------------------------------+-----+-------+
| Driver's license numbers                               |     |       |
+--------------------------------------------------------+-----+-------+

## If storing paper records of research data, answer the following questions:

### 

### Where will the paper records, including copies of signed consent forms, associated with this research study will be stored?

> \[Type protocol text here or indicate as not applicable\]

### How will the paper records be secured? 

> \[Type protocol text here or indicate as not applicable\]

### How will access to the paper records be restricted to authorized project personnel?

> \[Type protocol text here or indicate as not applicable\]

## If storing electronic records of research data, indicate where the electronic data associated with this research study will be stored. Check all that apply. 

> Penn State-provided database application. Check which of the following
> database applications are being used (check all that apply):
>
> Penn State REDCap
>
> Other -- Specify - provided and approved database application:
>
> \[Type protocol text here if box checked\]
>
> Penn State, College, or Department IT file server
>
> Penn State OneDrive or SharePoint
>
> Penn State GoogleDrive
>
> Web-based system provided by the sponsor or cooperative group -
> Specify URL and contact information:
>
> \[Type protocol text here if box checked\]
>
> Other -- Specify the database application or server:
>
> \[Type protocol text here if box checked\]
>
> Provide details about the data security features or attach security
> documentation provided by sponsor or group:
>
> \[Type protocol text here if box checked\]
>
> **Please visit**
> **[datastoragefinder.psu.edu](https://datastoragefinder.psu.edu/) for
> assistance with identifying appropriate data storage options. If the
> software to be used does not appear on that site, a [software request
> form](https://pennstate.qualtrics.com/jfe/form/SV_en6NEiMElsu35l3)
> must be completed.**
>
> If there is a list/key that links indirect identifiers (code numbers,
> participant IDs, etc.) to direct identifiers, that list must **not**
> be comingled (i.e., stored in the same location) as the identifiable
> data, including copies of signed informed consent forms. Additionally,
> access to that list/key must be restricted to authorized project
> personnel.

## Is there a list/key that links code numbers to identifiers? 

> Yes - explain how the list that links the code to identifiers is
> stored separately from coded data:
>
> \[Type protocol text here if box is checked\]
>
> Not applicable, there is no list that links code numbers to
> identifiers. Skip to section 22.6.

## Is there a list of people who have access to the list/key?

> Yes -- explain how access to that list is restricted and why certain
> persons require access.
>
> \[Type protocol text here if box is checked\]
>
> No -- explain why not:
>
> \[Type protocol text here if box is checked\]

## Describe the mechanism in place to ensure only approved research personnel have access to the stored research data (electronic and paper).

> Password-protected files
>
> Role-based security
>
> Specify all other mechanisms used to ensure only permitted users have
> access to the stored research data:
>
> \[Type protocol text here if box is checked\]
>
> The use of mobile devices or wireless activity trackers to collect
> identifiable research data may have to be approved by Penn State IT -
> Information Security.

## Will research data be stored on a mobile device, such as an electronic tablet/cell phone or will research data be collected on a wireless activity tracker? 

> No -- skip to 22.8
>
> Yes - answer the following questions:

### Specify the provider of the tracker or mobile devices(s)

> Supplied by the sponsor
>
> Penn State owned device
>
> A personal device
>
> Other -- Please specify source: \[Type protocol text here if box is
> checked\]

2.  **Specify the type(s) of tracker or mobile device(s) that will be
    used to capture data and all identifiers captured on the mobile
    device(s). Please list all devices, and if more than one, the
    identifiers to be collected on each.**

> \[Type protocol text here\]

### Specify the type of data collected on the tracker or mobile devices(s). 

> \[Type protocol text here\]

### Specify the application or website used to collect the data from the tracker or mobile device, if applicable.

> \[Type protocol text here\]

5.  **Describe the measures taken to protect the confidentiality of the
    data collected on the tracker or mobile device(s). Please address
    physical security of the device(s), electronic security, and secure
    transfer of data from device(s) to the previously indicated
    data/file storage location provided in section 22.3**.

> \[Type protocol text here\]

2.  Specify the

> The use of online survey tools and email to collect or send research
> data containing identifiers that represent more than minimal risk to
> subjects may have to be approved by Penn State IT - Information
> Security.

## Will any research data be directly entered/sent by subjects over the internet or via email (e.g., data capture using on-line surveys/questionnaires, surveys via email, observation of chat rooms or blogs)?

> No -- skip to 22.9
>
> Yes - answer the following questions:

### Specify the identifiers collected over the internet or via email (Including IP addresses if IP addresses will be collected).

> \[Type protocol text here\]

### Specify the type of data collected over the internet or via email.

> \[Type protocol text here\]

### Describe the measures taken to protect the confidentiality of the data collected?

> \[Type protocol text here\]

### Describe how the research team will access the data once data collection is complete.

> \[Type protocol text here\]

### If the research involves online surveys, list the name(s) of the service provider(s) that will be used for the survey(s) (e.g., REDCap, Penn State licensed Qualtrics, Survey Monkey, Zoomerang)? (Note: The IRB strongly recommends the use of REDCap for online surveys that obtain sensitive identifiable human subjects data.)

> Penn State REDCap
>
> Penn State Qualtrics
>
> Penn State Microsoft Forms
>
> Penn State Google Forms
>
> Other - Please specify:
>
> Application: \[Type protocol text here\]
>
> URL (If applicable): \[Type protocol text here\]

### If the answer above is "Other" contact <security@psu.edu> for approval of an alternative data capture method

> \[Type protocol text here\]
>
> Depending on the nature of the subject matter involved, certain
> security requirements must be in place for the audio and/or video
> recording or photographing of subjects. If the subject matter presents
> more than minimal risk to the subjects, then, before completing the
> section below, please contact Penn State IT - Information Security at
> <security@psu.edu> to confirm whether these requirements are required.

3.  Specify the

## Will any type of recordings (e.g., audio or video) or photographs of the subjects be made during this study?

> No - skip to section 22.10
>
> Yes - answer the following questions:

### What will be used to capture the audio/video/images? Give a brief description of content.

> Audio -- Describe the intended content of the audio recording:
>
> \[Type protocol text here\]
>
> Video -- Describe the intended content of the video recording:
>
> \[Type protocol text here\]
>
> Photographs of the subjects -- Describe the intended content of the
> photographs:
>
> \[Type protocol text here\]
>
> 3-D Images -- Describe the intended content of the of 3-D images:
>
> \[Type protocol text here\]
>
> Other - Specify:
>
> \[Type protocol text here\]

### How will the recordings/photographs/images be stored (electronically or physically)?

> \[Type protocol text here\]

### Where will the recordings/photographs/images be stored?

> \[Type protocol text here\]

### Who will have access to the recordings/photographs/images?

> \[Type protocol text here\]

### Will any of the recordings be transcribed?

> Not applicable
>
> No
>
> Yes -- indicate who will be doing the transcribing?
>
> \[Type protocol text here\]

### Will the recordings/photographs be used for purposes other than this research study?

> No
>
> Yes - specify purpose(s) (e.g., publication, presentations,
> educational training, future
>
> undetermined research):
>
> \[Type protocol text here\]

6.  What type of r

## Certificate of Confidentiality (COC) - Is the research biomedical, behavioral, clinical or other research that is funded by the National Institutes of Health (NIH)?

> Yes - check one of the following:
>
> The research involves human subjects as defined by the DHHS
> regulations (See Worksheet
>
> HRP-310).
>
> The research involves collecting or using biospecimens that are
> identifiable to an individual.
>
> If collecting or using biospecimens as part of the research, there is
> a small risk that some combination of the biospecimen, a request for
> the biospecimen, and other available data sources could be used to
> deduce the identity of an individual.
>
> The research involves the generation of individual level, human
> genomic data.
>
> **Note: If [any]{.underline} of the 4 items above are checked, a COC
> is automatically issued by NIH and applies to the research.
> Information about the COC must be included in the consent form.**
>
> No - answer the following question.
>
> If the research is not funded by NIH, will the investigator apply for
> a COC for this research study?
>
> No
>
> Yes
>
> **Note: For research not funded by NIH, the IRB may require a COC if
> the research is collecting personally identifiable information and the
> information is sensitive and/or the research is collecting information
> that if disclosed could significantly harm or damage the subject.**

## What steps will be taken to protect subjects' privacy interests? (Check all that apply.)

> Identification and recruitment of potential subjects follows
> procedures consistent with privacy standards
>
> Consent discussion and research interventions will take place in a
> private setting
>
> Limiting the information being collected to only the minimum amount of
> data necessary to accomplish the research purposes
>
> Limiting the people with access to the identifiable research data to
> the minimum necessary as specified in the application and consent
> process
>
> Other -- Specify:
>
> \[Type protocol text here\]

## What is the process for ensuring correctness of data entry?

> Double data entry to reduce risk of errors
>
> Electronic edit checks to ensure data being entered are not obviously
> incorrect
>
> Random internal quality and assurance checking of research data
>
> Direct entry by subjects
>
> Other - Specify:
>
> \[Type protocol text here\]

## Does this research involve the generation of large-scale human genomic data as defined in NIH Genomic Data Sharing Policy (<http://gds.nih.gov>)?

> No
>
> Yes -- describe the plan for de-identifying the dataset before sharing
> it with NIH-designated data repositories.
>
> \[Type protocol text here\]
>
> **Note: Data sharing with an NIH-designated data repository may
> require execution of an institutional certificate. Please review the
> 'Institutional Certification for NIH Genomic Data Sharing' section of
> the Investigator's Manual for information about seeking institutional
> certification.**

## Does this research involve transfer or disclosure of data and/or specimens to and/or from Penn State?

> No - skip the remainder of section 22.14
>
> Yes - answer the following questions:
>
> **Check all that apply:**
>
> **22.14.1** **Data** are being transferred or disclosed **to** Penn
> State
>
> What is the name of the third party(ies) (the institution, sponsor,
> etc.) sending or providing the data?
>
> \[Type protocol text here\]
>
> Is the third party requiring us to sign a contract regarding the data?
>
> **22.14.1.1** Yes - this contract must go through the Office of
> Sponsored Programs
> <https://www.research.psu.edu/osp/overview-pages/data-use-agreements>
>
> **22.14.1.2** No
>
> **22.14.2** **Data** are being transferred or disclosed **from** Penn
> State
>
> What is the name(s) of the third party(ies) (the institution, sponsor,
> etc.) receiving or accessing the data?
>
> \[Type protocol text here\]
>
> **Note: Data transfers or disclosures may require a Data Use Agreement
> (DUA).**
>
> **22.14.3** **Specimens** are being transferred **to** Penn State
>
> What is the name(s) of the third party(ies) (the institution, sponsor,
> etc.) sending the specimens?
>
> \[Type protocol text here\]
>
> **22.14.4** **Specimens** are being transferred **from** Penn State
>
> What is the name(s) of the third party(ies) (the institution, sponsor,
> etc.) receiving the specimens?
>
> \[Type protocol text here\]
>
> **Note: All material transfers, either sending or receiving, require a
> Material Transfer Agreement (MTA).Please contact the Office of
> Technology Management for more information.**

### 22.14.5 Describe how the data/specimens will be securely transferred or disclosed to/from the third party(ies).

> \[Type protocol text here\]

### 22.14.6 How are the research data/specimens being transferred from and/or sent to the third party(ies)? Complete the appropriate section(s) and check all that apply within each completed section.

#### 

#### 22.14.6.1 Data being transferred or disclosed to Penn State:

> Data are being received in aggregate/metrics (just counts, no
> individual data)
>
> De-identified individual data are being received and there is no
> linking list at either institution (no identifiers, or links to
> identifiers, such as code numbers)
>
> Coded research data [without]{.underline} any identifiers are being
> received and the linking list remains with the entity sending the
> data; the recipient of the data [will not]{.underline} have access to
> the linking list
>
> Coded research data [with]{.underline} identifiers (such as dates
> and/or any of the identifiers listed in section 22.14.7 aside from
> Study Code) are being received and the linking list remains with the
> entity sending the data; the recipient of the data [will
> not]{.underline} have access to the linking list
>
> Data [with]{.underline} identifiers (such as dates and/or any of the
> identifiers listed in section 22.14.7) are being received and the
> linking list remains with the entity sending the data; the recipient
> of the data [will]{.underline} have access to the linking list
>
> Data [with]{.underline} identifiers along with the linking list are
> being received
>
> Other -- Specify:
>
> \[Type protocol text here if box is checked\]

#### 22.14.6.2 Data being transferred or disclosed from Penn State:

> Data are being sent in aggregate/metrics (just counts, no individual
> data)
>
> De-identified individual data are being sent and there is no linking
> list at either institution (no identifiers, or links to identifiers,
> such as code numbers)
>
> Coded research data [without]{.underline} any identifiers are being
> sent and the linking list remains with the entity sending the data;
> the recipient of the data [will not]{.underline} have access to the
> linking list
>
> Coded research data [with]{.underline} identifiers (such as dates
> and/or any of the identifiers listed in section 22.14.7 aside from
> Study Code) are being sent and the linking list remains with the
> entity sending the data; the recipient of the data [will
> not]{.underline} have access to the linking list
>
> Data [with]{.underline} identifiers (such as dates and/or any of the
> identifiers listed in section 22.14.7) are being sent and the linking
> list remains with the entity sending the data; the recipient of the
> data [will]{.underline} have access to the linking list
>
> Data [with]{.underline} identifiers along with the linking list are
> being sent
>
> Other -- Specify:
>
> \[Type protocol text here if box is checked\]

#### 22.14.6.3 Specimens being transferred or disclosed to Penn State:

> De-identified specimens are being received and there is no linking
> list at either institution (no identifiers, or links to identifiers,
> such as code numbers)
>
> Coded specimens [without]{.underline} any identifiers are being
> received and the linking list remains with the entity sending the
> specimens; the recipient of the specimens [will not]{.underline} have
> access to the linking list
>
> Coded specimens [with]{.underline} identifiers (such as dates and/or
> any of the identifiers listed in section 22.14.7 aside from Study
> Code) are being received and the linking list remains with the entity
> sending the specimens; the recipient of the specimens [will
> not]{.underline} have access to the linking list
>
> Coded specimens [with]{.underline} identifiers (such as dates and/or
> any of the identifiers listed in section 22.14.7) are being received
> and the linking list remains with the entity sending the specimens;
> the recipient of the specimens [will]{.underline} have access to the
> linking list
>
> Coded specimens [with]{.underline} identifiers along with the linking
> list are being received
>
> Other -- Specify:
>
> \[Type protocol text here if box is checked\]

#### 22.14.6.4 Specimens being transferred or disclosed from Penn State:

> De-identified specimens are being sent and there is no linking list at
> either institution (no identifiers, or links to identifiers, such as
> code numbers)
>
> Coded specimens [without]{.underline} any identifiers are being sent
> and the linking list remains with the entity sending the specimens;
> the recipient of the specimens [will not]{.underline} have access to
> the linking list
>
> Coded specimens [with]{.underline} identifiers (such as dates and/or
> any of the identifiers listed in section 22.14.7 aside from Study
> Code) are being sent and the linking list remains with the entity
> sending the specimens; the recipient of the specimens [will
> not]{.underline} have access to the linking list
>
> Coded specimens [with]{.underline} identifiers (such as dates and/or
> any of the identifiers listed in section 22.14.7) are being sent and
> the linking list remains with the entity sending the specimens; the
> recipient of the specimens [will]{.underline} have access to the
> linking list
>
> Coded specimens [with]{.underline} identifiers along with the linking
> list are being sent
>
> Other -- Specify:
>
> \[Type protocol text here if box is checked\]

### 22.14.7 If transferring data/specimens with identifiers to or from Penn State, which of the following identifiers will be included with the data/specimens? Check all that apply:

+-----------------------------+----------------------------------------+
| Names                       | Medical record numbers                 |
+=============================+========================================+
| Initials                    | Health plan beneficiary numbers        |
+-----------------------------+----------------------------------------+
| Street address              | Account numbers                        |
+-----------------------------+----------------------------------------+
| City                        | Certificate/license numbers            |
+-----------------------------+----------------------------------------+
| Driver's License numbers    | Passport numbers                       |
+-----------------------------+----------------------------------------+
| State                       | State ID numbers                       |
+-----------------------------+----------------------------------------+
| Zip Codes                   | Vehicle identifiers and serial         |
|                             | numbers, including license plate       |
|                             | numbers                                |
+-----------------------------+----------------------------------------+
| County                      | Device identifiers and serial numbers  |
+-----------------------------+----------------------------------------+
| Geocodes                    | Web Universal Resource Locators (URLs) |
+-----------------------------+----------------------------------------+
| Precincts                   | Internet Protocol (IP) address numbers |
+-----------------------------+----------------------------------------+
| All elements of dates       | Biometric identifiers, including       |
| (except year) for dates     | finger and voice prints                |
| directly related to an      |                                        |
| individual, including birth |                                        |
| date, admission date,       |                                        |
| discharge date, date of     |                                        |
| death                       |                                        |
+-----------------------------+----------------------------------------+
| Ages \> 89 and all elements | Full face photographic images and any  |
| of dates (including year)   | comparable images                      |
| indicative of such age,     |                                        |
| except that such ages and   |                                        |
| elements may be aggregated  |                                        |
| into a single category of   |                                        |
| age 90 or older             |                                        |
+-----------------------------+----------------------------------------+
| Telephone numbers           | Any other unique identifying number,   |
|                             | characteristic, or code (such as the   |
|                             | pathology number)                      |
|                             |                                        |
|                             | Specify: \[Type protocol text here if  |
|                             | box is checked\]                       |
+-----------------------------+----------------------------------------+
| Fax numbers                 | Study code numbers                     |
+-----------------------------+----------------------------------------+
| Electronic mail addresses   | Master list linking study code numbers |
|                             | to subject(s)                          |
+-----------------------------+----------------------------------------+
| Social security numbers     | Genomic sequence data                  |
+-----------------------------+----------------------------------------+
|                             | Other -- specify: \[Type protocol text |
|                             | here if box is checked\]               |
+-----------------------------+----------------------------------------+

[^1]: This template satisfies AAHRPP elements 1.7.B, I.8.B, I-9, II.2.
    A, II.2.I, II.3.A, II.3.B, II.3.C-II.3.C.1, II.3.D-F, II.4.A,
    III.1.C-F, II.2.D
